Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2019 | 12-2018 | 09-2018 | 06-2018 | 03-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 134,275 | 147,871 | 163,323 | N/A | N/A |
| Other current assets | 2,759 | 3,661 | 2,721 | 0 | 0 |
| TOTAL | $137,034 | $151,532 | $166,044 | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 400 | 205 | 162 | N/A | N/A |
| Other Non-Current Assets | 2,563 | 187 | 188 | 0 | 0 |
| TOTAL | $2,963 | $392 | $350 | $N/A | $N/A |
| Total Assets | $139,997 | $151,924 | $166,394 | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,907 | 5,872 | 6,827 | 0 | 0 |
| Accrued Expenses | 3,877 | 3,251 | 2,489 | N/A | N/A |
| TOTAL | $10,301 | $9,123 | $9,316 | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 4,183 | 2,274 | 2,050 | 0 | 0 |
| TOTAL | $4,183 | $2,274 | $2,050 | $N/A | $N/A |
| Total Liabilities | $14,484 | $11,397 | $11,366 | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 34,194 | 34,194 | 34,194 | N/A | N/A |
| Common Shares | 3 | 3 | 3 | N/A | N/A |
| Retained earnings | -100,769 | -84,835 | -70,775 | N/A | N/A |
| Other shareholders' equity | 63 | 7 | -48 | 0 | 0 |
| TOTAL | $125,513 | $140,527 | $155,028 | $N/A | $N/A |
| Total Liabilities And Equity | $139,997 | $151,924 | $166,394 | $0 | $0 |